New weekly jab targets long-lasting weight loss

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleScientists have developed a new weekly weight loss jab, RES-010, which targets the RNA molecule miR-22, a key regulator of obesity-related processes. RES-010 aims to achieve long-lasting weight loss by reprogramming how cells handle fat and energy, boosting mitochondria and converting white fat into brown fat, with initial mouse studies showing promising results. A separate study revealed that tirzepatide, marketed as Mounjaro, significantly improved blood sugar control and reduced BMI in young people aged 10 to 17 with type 2 diabetes. This research indicated that 79% of young participants on tirzepatide achieved target blood sugar levels after 30 weeks, providing a potential new treatment for youth-onset type 2 diabetes. Eli Lilly's new weight loss pill, orforglipron, demonstrated superior blood sugar reduction and greater weight loss compared to oral semaglutide in a head-to-head study involving adults with type 2 diabetes. In fullNew type of jab helps to maintain weight lossThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata daindependent.co.uk